Dr. Jack Cush reviews highlight abstracts and sessions – covering lupus, RA, gout, Still’s disease, safety data, AI in medicine and more – from last week’s EULAR 2023 Congress held in Milan, Italy.

Lupus

• OP0053: EFFICACY AND SAFETY OF BARICITINIB IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 TRIAL
• OP0137: Efficacy and Safety of telitacicept, a novel BLyS/APRIL dual inhibitor, in patients with systemic lupus erythematosus: a phase 3, randomized, placebo-controlled 52-week study
• POS0120: Safety and efficacy of subcutaneous (s.c.) dose ianalumab (VAY736; anti-BAFFR mAb) administered monthly over 28 weeks in patients with systemic lupus erythematosus (SLE)
• OP0139: Efficacy and Safety of ABBV-599 High Dose (Elsubrutinib 60 mg and Upadacitinib 30 mg) and Upadacitinib Monotherapy for the Treatment of Systemic Lupus Erythematosus: A Phase 2, Double-blind, Placebo-controlled Trial
• POS0112: Deucravacitinib Reduces Interferons, B-cell Pathways, and Serological Biomarkers of Systemic Lupus Disease Activity: Pharmacodynamic Analysis from the Phase 2 PAISLEY Study

Rheumatoid Arthritis

• OP0272: Early response in rheumatoid factor levels predicts subsequent clinical response to disease modifying treatment of rheumatoid arthritis
• OP0130: Abatacept in individuals at risk of developing rheumatoid arthritis: results from the Arthritis Prevention in the Pre-clinical Phase of RA with Abatacept (APIPPRA) trial
• LB0001: Head-to-Head Comparison of TLL-018 and Tofacitinib in Patients with Active Rheumatoid Arthritis: Interim Results from a Phase IIa Study
• OP0219: Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with JAK-inhibitors compared to bDMARDs: data from an international collaboration of registries (the “JAK-pot” study)

Gout

• LB0002: SAFETY & EFFICACY OF SEL-212 IN PATIENTS WITH GOUT REFRACTORY TO COVENTIONAL TREATMENT: OUTCOMES FROM TWO RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE III STUDIES
• OP0295: A 12-Week, Randomized, Double-Blinded, Placebo-Controlled, Phase 2b Study of Safety, Tolerability and Efficacy of AR882 in Gout Patients

Long Term Studies

• OP0141: LONG TERM SAFETY AND EFFICACY OF CAR-T CELL TREATMENT IN REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS – DATA FROM THE FIRST SEVEN PATIENTS
• OP0166: Long-term follow-up of patients administered emapalumab, an anti–interferon-γ monoclonal antibody, to treat macrophage activation syndrome (MAS) secondary to systemic juvenile idiopathic arthritis (sJIA)

Stills Disease

• AB1503 (2023)  I. DI Cola1, F. Ursini2,3, R. Giacomelli4, P. Cipriani1, P. Ruscitti. THE IMPACT OF OBESITY ON CLINICAL COURSE AND BIOLOGIC DMARD FAILURE IN PATIENTS WITH ADULT ONSET STILL’S DISEASE
• OP0034 (2023)  D. Foell, et al. A NOVEL SERUM CALPROTECTIN (MRP8/14) PARTICLE ENHANCED IMMUNO-TURBIDIMETRIC ASSAY (SCAL TURBO) HELPS TO DIFFERENTIATE SJIA FROM OTHER DISEASES IN ROUTINE CLINICAL LABORATORY SETTINGS

Artificial Intelligence in Medicine: Chances & Challenges – Predicting RA, Reading and Progression of Xrays and best therapies

Author: